Market Currents
Repros Therapeutics (RPRX +1.7%) provides a clinical update of its Phase 3 DEXA study, saying...
-
Monday, January 7, 2:45 PM ETRepros Therapeutics (RPRX +1.7%) provides a clinical update of its Phase 3 DEXA study, saying that recruiting is running better than expected, and that 83% of men with secondary hypogonadism are on target to be successfully treated with no testosterone levels achieved beyond the normal range. Enrollment should ensure mid-2014 NDA submission.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
